Mervyn Israel, Ph.D.
Professor of Pharmacology, College of Medicine
Professor of Pharmaceutical Sciences, College of Pharmacy
Room 431 Crowe Research Building
(901) 448-4584
FAX (901) 448-4587
misrael@utmem.edu
Education:
Brooklyn College, Brooklyn, NY B.S. 1955 Chemistry/Biology
University of Pennsylvania, Philadelphia, PA M.S. 1956 Medicinal Chemistry/Chemotherapy
University of Pennsylvania, Philadelphia, PA Ph.D. 1959 Medicinal Chemistry/Chemotherapy
Postdoctoral Appointments: University of Michigan (1958-59); Harvard University (1959-60)
Research Interests:
Cancer chemotherapy and pharmacology; experimental and developmental therapeutics; mechanisms of cancer drug action; metabolism and disposition; pharmacokinetics; clinical pharmacology
Selected Publications:
L.F. Chuang, H.-F. King, M. Israel, and R.Y. Chuang. Activation of human leukemia protein kinase C by tumor promotors: Inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32). Biochemical Pharmacology, 43: 865, 1992.
C. Romano, K. Williams, S. DePriest, R. Seshadri, G.R. Marshall, M. Israel, and P.B. Molinoff. Effects of mono-, di-, and triamines on the NMDA receptor complex: A model of the polyamine recognition site. Molecular Pharmacology, 41: 785, 1992.
L. Lothstein, T.W. Sweatman, M.E. Dockter, and M. Israel. Resistance to N-benzyladriamycin-14-valerate (AD 198) in mouse J774-2 cells: P-glycoprotein expression without enhanced AD 198 efflux. Cancer Research, 52: 3409, 1992.
K.N. Thimmaiah, J.K. Horton, R. Seshadri, M. Israel, J.A. Houghton, F.C. Harwood, and P.J. Houghton. Synthesis and characterization of N-substituted phenoxazines directed towards reversing vinca alkaloid resistance in multidrug resistant cancer cells. Journal of Medicinal Chemistry, 35: 3358, 1992.
L. Lothstein, H.M. Wright, T.W. Sweatman, and M. Israel. N-Benzyladriamycin-14-valerate and drug resistance: Correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells. Oncology Research, 4: 341, 1992.
A. Harstrick, N. Schleucher, U. Vanhoefer, M. Israel, S. Seeber, and H. Wilke. High activity of N-benzyladriamycin-14-valerate (AD 198), a new anthracycline not transported by p-glycoprotein in multidrug resistant human ovarian and breast carcinoma cell lines. Annals of Hematology, 67: A180, 1993.
C. Dass, K.N. Thimmaiah, B.S. Jayashree, R. Seshadri, M. Israel, and P.J. Houghton. Analysis of Phenoxazine Chemosensitizers: An Electron Ionization and keV-Ion Beam Bombardment Mass Spectrometry Study. Biological Mass Spectrometry, 23: 140, 1994.
B.J. Zimmerman, S.A. McCormack, M. Israel, and L.R. Johnson. Polyamine-mediated cell migration and growth: Structural requirements for diamine analogues to substitute for putrescine. Cellular Pharmacology, 2: 109, 1995.
S.A. McCormack, B.J. Zimmerman, M. Israel, P. Blanner, and L.R. Johnson. Structural requirements of analogues of polyamines for migration and growth of IEC-6 cells. Molecular Pharmacology, 48: 724, 1995.
G. Han, M. Israel, R. Seshadri, J.T. Dalton, and T.W. Sweatman. Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. Cancer Chemotherapy and Pharmacology, 37: 472, 1996.
M. Markman, H. Homesley, D.A. Norbergs, J. Schink, F. Abbas, A. Miller, J. Soper, N. Teng, N. Hammond, F. Muggia, M. Israel, and T.W. Sweatman. Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies. Gynecologic Oncology, 61: 90, 1996.
T.W. Sweatman and M Israel. Anthracyclines. Chapter 5, in "Cancer Therapeutics: Experimental and Clinical Agents", B.A. Teicher, Ed. Humana Press, Totowa, NJ, 1996, pp.113-136.
T.J. Lampidis, D. Kolonias, T. Podona, M. Israel, A.R. Safa, L. Lothstein, N. Saravaj, H. Tapiero, and W. Priebe. Circumvention of P-gp MDR as a function of anthracycline lipophilicity and charge. Biochemistry, 1997, in press.